ANI Pharmaceuticals Inc (NASDAQ:ANIP) Director Tracy Marshbanks sold 64,221 shares of the stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $63.03, for a total value of $4,047,849.63. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Tracy Marshbanks also recently made the following trade(s):
- On Thursday, March 8th, Tracy Marshbanks sold 15,391 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $63.08, for a total value of $970,864.28.
Shares of ANI Pharmaceuticals Inc (ANIP) traded down $0.13 during trading on Monday, hitting $62.75. 103,252 shares of the stock traded hands, compared to its average volume of 164,378. The firm has a market capitalization of $730.60, a P/E ratio of 59.20 and a beta of 2.75. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.39 and a current ratio of 3.36. ANI Pharmaceuticals Inc has a twelve month low of $42.23 and a twelve month high of $74.70.
Several brokerages have commented on ANIP. BidaskClub downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 24th. ValuEngine downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th. TheStreet downgraded ANI Pharmaceuticals from a “b” rating to a “c+” rating in a report on Tuesday, February 20th. Zacks Investment Research downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, Canaccord Genuity set a $77.00 price objective on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. ANI Pharmaceuticals has an average rating of “Hold” and a consensus target price of $72.25.
Institutional investors have recently made changes to their positions in the company. Bank of Montreal Can grew its stake in shares of ANI Pharmaceuticals by 681.8% in the fourth quarter. Bank of Montreal Can now owns 2,408 shares of the specialty pharmaceutical company’s stock worth $156,000 after acquiring an additional 2,100 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth $210,000. Driehaus Capital Management LLC bought a new position in ANI Pharmaceuticals in the fourth quarter worth $220,000. SG Americas Securities LLC bought a new position in ANI Pharmaceuticals in the third quarter worth $197,000. Finally, Louisiana State Employees Retirement System bought a new position in ANI Pharmaceuticals in the fourth quarter worth $251,000. Institutional investors and hedge funds own 55.95% of the company’s stock.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.